Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
Mallinckrodt
Chubb
McKinsey
Daiichi Sankyo
Citi
Medtronic
Novartis
Johnson and Johnson
Deloitte

Generated: August 23, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 208026

« Back to Dashboard
NDA 208026 describes JENTADUETO XR, which is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from one supplier. There are sixteen patents protecting this drug. Additional details are available on the JENTADUETO XR profile page.

The generic ingredient in JENTADUETO XR is linagliptin; metformin hydrochloride. There are seventeen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the linagliptin; metformin hydrochloride profile page.

Summary for NDA: 208026

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:16
Formulation / Manufacturing:see details

Pharmacology for NDA: 208026

Ingredient-typeBiguanides
Mechanism of ActionDipeptidyl Peptidase 4 Inhibitors

Suppliers and Packaging for NDA: 208026

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
JENTADUETO XR
linagliptin; metformin hydrochloride
TABLET, EXTENDED RELEASE;ORAL 208026 NDA Boehringer Ingelheim Pharmaceuticals, Inc. 0597-0270 0597-0270-12 1 BOTTLE in 1 CARTON (0597-0270-12) > 14 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE
JENTADUETO XR
linagliptin; metformin hydrochloride
TABLET, EXTENDED RELEASE;ORAL 208026 NDA Boehringer Ingelheim Pharmaceuticals, Inc. 0597-0270 0597-0270-73 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0597-0270-73)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength2.5MG;1GM
Approval Date:May 27, 2016TE:RLD:Yes
Patent:► SubscribePatent Expiration:Jun 20, 2020Product Flag?YSubstance Flag?Delist Request?
Patent:► SubscribePatent Expiration:Sep 19, 2016Product Flag?YSubstance Flag?Delist Request?
Patent:► SubscribePatent Expiration:May 2, 2025Product Flag?YSubstance Flag?YDelist Request?

Expired Orange Book Patents for NDA: 208026

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Boehringer Ingelheim
JENTADUETO XR
linagliptin; metformin hydrochloride
TABLET, EXTENDED RELEASE;ORAL208026-001May 27, 2016► Subscribe► Subscribe
Boehringer Ingelheim
JENTADUETO XR
linagliptin; metformin hydrochloride
TABLET, EXTENDED RELEASE;ORAL208026-002May 27, 2016► Subscribe► Subscribe
Boehringer Ingelheim
JENTADUETO XR
linagliptin; metformin hydrochloride
TABLET, EXTENDED RELEASE;ORAL208026-001May 27, 2016► Subscribe► Subscribe
Boehringer Ingelheim
JENTADUETO XR
linagliptin; metformin hydrochloride
TABLET, EXTENDED RELEASE;ORAL208026-002May 27, 2016► Subscribe► Subscribe
Boehringer Ingelheim
JENTADUETO XR
linagliptin; metformin hydrochloride
TABLET, EXTENDED RELEASE;ORAL208026-002May 27, 2016► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Healthtrust
UBS
Daiichi Sankyo
Johnson and Johnson
Chinese Patent Office
Accenture
McKesson
Fuji
Deloitte
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot